Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Clinical trial NCT02001623 · COMPLETED

Trial details

NCT number: NCT02001623
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ovary Cancer Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer (CRPC)Esophagus Cancer Lung Cancer(NSCLC)Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Start date: 2013-11-30
Primary completion: 2019-05-02
Enrollment: 195

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.